New drug shows promise in battle against rare kidney disease
NCT ID NCT06513338
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tested a new antibody drug (C5 monoclonal antibody) in 16 people with anti-GBM disease, a severe autoimmune condition that attacks the kidneys. The goal was to see if the drug could prevent kidney failure better than current treatments. The approach targets part of the immune system called complement to reduce kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, 100038, China
Conditions
Explore the condition pages connected to this study.